2025 International Sublobar Resections and Bronchoscopic Ablation Summit (ISC 2025)
Vergent Bioscience is an official sponsor of ISC 2025
Thank You for Your Interest in Vergent Bioscience!
Keep scrolling for helpful information and resources about Vergent and abenacianine for injection (VGT-309), an investigational surgical imaging agent with potential to provide clinical, technical, and commercial advantages compared to other intraoperative imaging agents.
Learn more about Vergent Bioscience, abenacianine, and our VISUALIZE clinical trial below.
Abenacianine for Injection Fact Sheet
Vergent’s lead compound, abenacianine for injection (VGT-309), is an investigational tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures.
Publication
Phase 2 Clinical Trial of VGT-309 for Intraoperative Molecular Imaging During Pulmonary Resection. The Annals of Thoracic Surgery. 2024
Optimizing Sublobar Resection – Clinical Impact of Intraoperative Molecular Imaging with VGT-309
Date: 10 January 2025 | Time: 12:10 - 12:40PM
DON'T MISS IT!
ISC 2025 presentation from Gavin Wright, Ph.D.
Follow us on LinkedIn and X for continued updates:
In 2024, Vergent Bioscience completed patient enrollment in its Phase 2b multicenter VISUALIZE study, designed to evaluate the efficacy and safety of abenacianine in patients undergoing surgery for cancer in the lung. Vergent intends to advance abenacianine into the VISUALIZE-2 Phase 3 study in 2025.